Moderna, Merck cancer vaccine shows promise in late-stage trial

Merc is up by about 5.8%. Madna shares are up by 70% this morning. It's a gain of more than $43 to $107.3%.This comes on positive topline results from a large phase 3 trial of the two companies melanoma treatment. It combines individualized mRNA based therapy with Merc's Kitruda for patients who have had melanoma surgically removed. That trial did meet both its primary and secondary endpoints of survival without recurrence of the cancer as well as survival without the cancer spreading to other parts of the ...